Evidence map›Paper›PMID 34230999›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2021

Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.

A R Gonciulea, Y Wang, D D Bikle, D E Sellmeyer

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

A R GonciuleaDivision of Endocrinology, Yale New Haven Health NEMG, Fairfield, CT, USA.
Y WangDepartment of Medicine, University of California San Francisco, San Francisco, USA.
D D BikleDepartment of Medicine, University of California San Francisco, San Francisco, USA.
D E SellmeyerDivision of Endocrinology, Gerontology and Metabolism, Stanford University School of Medicine, 300 Pasteur Dr. M/C 5103, Palo Alto, CA, 94305, USA. dsellme@stanford.edu.
San Francisco VA Medical Center · USStanford University · USUniversity of California, San Francisco · USYale New Haven Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercalcemia occurs in up to 30% of patients with malignancies and can be due to osteolysis by metastases, parathyroid hormone-related protein (PTHrP), excess 1,25-dihydroxyvitamin D (1,25(OH)

Indexed as

HypercalcemiaLymphoma, Non-HodgkinCalcitriolCalciumFemaleHumansParathyroid HormoneParathyroid Hormone-Related ProteinVitamin D1,25-dihydroxyvitamin DCalcitriolCalciumParathyroid HormoneParathyroid Hormone-Related ProteinVitamin D1,25-dihydroxyvitamin D,hypercalcemia,malignancy,PTHrP

Identifiers

PMID34230999
OpenAlexW3180681137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.